UK markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4400-0.0400 (-2.70%)
At close: 04:00PM EDT
1.4491 +0.01 (+0.63%)
After hours: 07:50PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 301.82M
Enterprise value 302.71M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.48
Price/book (mrq)N/A
Enterprise value/revenue 1.62
Enterprise value/EBITDA 198.11

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-13.77%
S&P500 52-week change 318.96%
52-week high 32.4800
52-week low 30.7800
50-day moving average 31.1289
200-day moving average 31.2834

Share statistics

Avg vol (3-month) 33.24M
Avg vol (10-day) 32.41M
Shares outstanding 5209.6M
Implied shares outstanding 6209.6M
Float 8203.83M
% held by insiders 12.14%
% held by institutions 127.34%
Shares short (15 Jul 2024) 418.66M
Short ratio (15 Jul 2024) 43.93
Short % of float (15 Jul 2024) 49.00%
Short % of shares outstanding (15 Jul 2024) 48.90%
Shares short (prior month 14 Jun 2024) 412.3M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -22.99%
Operating margin (ttm)-43.82%

Management effectiveness

Return on assets (ttm)-8.37%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)187.22M
Revenue per share (ttm)0.97
Quarterly revenue growth (yoy)-18.50%
Gross profit (ttm)N/A
EBITDA 3.97M
Net income avi to common (ttm)-43.03M
Diluted EPS (ttm)-0.2200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)41.96M
Total cash per share (mrq)0.2
Total debt (mrq)98.34M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.70
Book value per share (mrq)-0.13

Cash flow statement

Operating cash flow (ttm)-25.28M
Levered free cash flow (ttm)24.05M